Comparative Pharmacology
Head-to-head clinical analysis: CLARITHROMYCIN versus ILOSONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITHROMYCIN versus ILOSONE.
CLARITHROMYCIN vs ILOSONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clarithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, specifically to the 23S rRNA component, blocking peptide chain elongation and exerting bacteriostatic or bactericidal effects depending on concentration and organism.
Erythromycin (ILOSONE) binds to the 50S subunit of bacterial ribosomes, inhibiting peptide chain elongation and protein synthesis by blocking translocation.
250-500 mg orally twice daily for 7-14 days; for MAC infection: 500 mg twice daily.
Erythromycin (Ilosone) base or stearate: 250-500 mg orally every 6 hours. Estolate: 250-500 mg orally every 6 hours. Maximum dose 4 g/day.
None Documented
None Documented
Clinical Note
moderateClarithromycin + Levofloxacin
"Clarithromycin may increase the QTc-prolonging activities of Levofloxacin."
Clinical Note
moderateClarithromycin + Norfloxacin
"Clarithromycin may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateClarithromycin + Gemifloxacin
"Clarithromycin may increase the QTc-prolonging activities of Gemifloxacin."
Clinical Note
moderateClarithromycin + Haloperidol
Terminal elimination half-life: 5-7 hours in adults with normal renal function; prolonged to 8-12 hours in moderate to severe renal impairment; clinical context: allows twice-daily dosing; active metabolite (14-hydroxyclarithromycin) half-life similar.
1.5-2 hours in adults; prolonged in hepatic impairment (up to 5-6 hours)
Renal: approximately 30-40% unchanged; biliary/fecal: approximately 40-50% as metabolites; total renal clearance accounts for about 30-40% of dose; hepatic metabolism contributes to elimination; dose adjustment required in severe renal impairment (CrCl <30 mL/min).
Renal (2-5% unchanged), biliary/fecal (majority, >90% as metabolites and unchanged drug)
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic
"Clarithromycin may increase the QTc-prolonging activities of Haloperidol."